Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

214
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
214
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

146
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
146
Drug Delivery: Enteral Route01:18

Drug Delivery: Enteral Route

1.5K
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
1.5K
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

148
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
148
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

496
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
496
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

554
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
554

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same authorSame journal

Comparison of essential drug lists: concordance, differences, and the need for core lists in times of crisis.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

Comparative analysis of ligand binding affinities and functional profiles at recombinant human β-adrenergic receptor subtypes 1, 2, and 3.

The Journal of pharmacology and experimental therapeutics·2026
Same author

Binding affinities for histamine receptors 1 to 4: Systematic comparison of ligands from the Psychoactive Drug Screening Program K<sub>i</sub> database and International Union of Basic and Clinical Pharmacology/British Pharmacological Society Guide to Pharmacology.

Molecular pharmacology·2026
Same author

A new chapter in the history of Naunyn-Schmiedebergs Archives of Pharmacology: appointment of international deputy editors.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

Critical analysis of digitalis glycosides: declining use but increasing poison-center exposure cases for digitoxin.

European journal of clinical pharmacology·2026
Same author

A Survey of German Dentists on the Prophylactic Use of Antibacterial Drugs in Patients in Risk Groups: Diabetes, Joint Replacement, Risk of Endocarditis, and Immunosuppression or Organ Transplantation.

International journal of dentistry·2026

相关实验视频

Updated: Jan 6, 2026

Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease
06:06

Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease

Published on: May 9, 2022

3.0K

包装插件之间关于牙过度生长导致药物的变化.

Philipp Friedrich Georg Ried1, Roland Seifert2

  • 1Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625, Hannover, Germany.

Naunyn-Schmiedeberg's archives of pharmacology
|November 27, 2025
PubMed
概括

药物诱导的牙过度生长 (DIGO) 是一种严重的药物不良反应. 尽管处方率较低,但瓦尔酸治疗具有最高的DIGO风险,需要仔细监测患者.

关键词:
药物不良反应 药物不良反应抗药是一种抗药.通道阻塞剂 通道阻塞剂迪戈 (DIGO) 是一个药物诱导的牙过度生长.免疫抑制剂 免疫抑制剂包装插件 包装插件

更多相关视频

Induction of Periodontitis via a Combination of Ligature and Lipopolysaccharide Injection in a Rat Model
06:14

Induction of Periodontitis via a Combination of Ligature and Lipopolysaccharide Injection in a Rat Model

Published on: February 17, 2023

5.0K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

相关实验视频

Last Updated: Jan 6, 2026

Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease
06:06

Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease

Published on: May 9, 2022

3.0K
Induction of Periodontitis via a Combination of Ligature and Lipopolysaccharide Injection in a Rat Model
06:14

Induction of Periodontitis via a Combination of Ligature and Lipopolysaccharide Injection in a Rat Model

Published on: February 17, 2023

5.0K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

科学领域:

  • 药理学和牙科 药理学和牙科
  • 药物不良反应 药物不良反应
  • 药物安全监测监测 药物安全监测

背景情况:

  • 药物诱导的牙过度生长 (DIGO) 是一种常见的不良药物反应,与诸如管阻断剂,抗药和免疫抑制剂等高处方药物有关.
  • 报告的药物不良反应 (ADR) 频率存在于药物包装插件 (PI) 和产品特性摘要 (SmPC) 的变化.

研究的目的:

  • 将不同药物类别的DIGO风险进行比较,并确定具有诱导这种情况的最高倾向的特定药物.
  • 分析和比较来自不同制造商的PI和SmPC中关于DIGO的信息.
  • 根据处方数据和报告的流行情况,估计德国每年的DIGO发病率.

主要方法:

  • 已知导致DIGO (通道阻断剂,抗药,免疫抑制剂) 的药物类别的比较分析.
  • 对PI和SmPC进行评估,以查看DIGO信息的不一致性和完整性.
  • 模型计算使用2023年德国药物处方数据 (Arzneiverordnungsreport) 和PI流行率来估计DIGO发生率.

主要成果:

  • 在不同药物包装插件中观察到报告的DIGO频率和ADR的显著差异.
  • 产品特征摘要 (SmPC) 往往提供了与PI相比,对DIGO的详细或不太准确的信息.
  • 长期的酸治疗与最高的DIGO率有关,超过了像阿姆洛迪平或芬尼托因等更频繁处方的药物.

结论:

  • 包装插件和SmPC显示DIGO报告中的不一致性,影响医疗保健专业信息.
  • 瓦尔酸对DIGO构成重大风险,需要对接受长期治疗的患者进行警监测.
  • 早期检测和干预对于管理DIGO至关重要,特别是在接受酸治疗的患者中.